Clinical trial
A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT07029945 is registered in ClinicalTrials.gov with Biojiva LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Lead sponsor
- Biojiva LLC
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- September 29, 2026
- Completion date
- April 30, 2029
- Enrollment
- 152 (estimated)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.